Skip Ribbon Commands
Skip to main content
NL FR
A
A
A

 Publicaties

 Publications

  

  

Publicaties Régine Kiasuwa Mbengi
Publicaties Marc Arbyn
 

 

  • Bosch FX, Robles C, Diaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2015.
  • Cuschieri K, Geraets D, Moore C, Quint W, Duvall E, Arbyn M. Clinical and analytical performance of the Onclarity HPV assay using the VALGENT framework. J Clin Microbiol 2015; in-press.
  • European Commission. Anttila A, Arbyn M, De Vuyst H, Dillner J, Franceschi S, Patnick J, Segnan N, Tornberg S, von Karsa L, editors. Luxembourg: Office for Official Publications of the European Communities, 2015. pp. 1-167.
  • Feoli F, Renard C, Abouyahia M, De Winda R, Larsimont D, Arbyn M. Retrospective Rescreening of Negative Cervical Cytology Samples preceding CIN2-3+: An Educational Opportunity To Understand and to Prevent Laboratory Errors. Acta Cytol 2015; accepted-for publication.
  • Giorgi-Rossi P, Arbyn M, et.al. Why follow-back studies should be interpreted cautiously: the case of HPV negative cervical lesion. Cancer Cytopathol 2015; in-press.
  • Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJF, Arbyn M. Reaching women who do not participate in the regular cervical cancer screening program by offering self-sampling kits: A systematic review and meta-analysis of randomised trials. Eur J Cancer 2015; in-press.
  • von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavir Res 2015.
 
  • Arbyn, M., Van Casteren, V., and Van Hoof, E. Prevention of Cervical Cancer in Belgium: Anno 2011. PHS Report 2010/010, 1-118. 2011. Brussels, Scientific Institute of Public Health (WIV-ISP).
  • Arbyn, M., Simoens, C., Fabri, V., and Swennen, B. Prophylactic vaccination of girls and female adolescents against human papilomavirus infection (Belgium, 2007-2009). IPH/EPI-REPORTS , 1-50. 2011. Brussels, Scientific Institute Public Health (WIV-ISP); Agence Intermutualiste/Intermutualistisch Agentschap (AIM/IMA).
​​​​
Publications de Régine Kiasuwa Mbengi

Publications de Marc Arbyn

  • Arbyn M, Xu L, Simoens C, Martin-Hirsch PPL. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Library (Communiqué du 09-05-2018)
  • Arbyn M, Castle P. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol Biomarkers Prev 2015; 24: 769-72.
  • Arbyn M, Haelens A, Desomer A, Verdoodt F, Thiry N, Francart J, Hanquet G, Robays J. Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening. KCE reports 2015; 238: 1-282.
  • Arbyn M, Snijders PJ, Meijer CJ, Berkhof H, Cuschieri K, Kocjan BJ, Poljak M. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect 2015; in-press.
  • Bosch FX, Robles C, Diaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2015.
  • Cuschieri K, Geraets D, Moore C, Quint W, Duvall E, Arbyn M. Clinical and analytical performance of the Onclarity HPV assay using the VALGENT framework. J Clin Microbiol 2015; in-press.
  • European Commission. Anttila A, Arbyn M, De Vuyst H, Dillner J, Franceschi S, Patnick J, Segnan N, Tornberg S, von Karsa L, editors. Luxembourg: Office for Official Publications of the European Communities, 2015. pp. 1-167.
  • Feoli F, Renard C, Abouyahia M, De Winda R, Larsimont D, Arbyn M. Retrospective Rescreening of Negative Cervical Cytology Samples preceding CIN2-3+: An Educational Opportunity To Understand and to Prevent Laboratory Errors. Acta Cytol 2015; accepted-for publication.
  • Giorgi-Rossi P, Arbyn M, et.al. Why follow-back studies should be interpreted cautiously: the case of HPV negative cervical lesion. Cancer Cytopathol 2015; in-press.
  • Finoulst M, Vankrunkelsven P, Robays J, Arbyn M. Waarom de screening voor cervixkanker best wordt aangepast. Tijdschr Geneeskunde 2015; 71: 257-60.
  • Giorgi-Rossi P, Arbyn M, Meijer CJLM. Cervical cancer screening by human papillomavirus testing followed by cytology triage. JAMA Int Med 2015; 175: 1068.
  • Merckx M, Vanden Broeck D, Benoy I, Depuydt C, Arbyn M. Early effects of HPV vaccination in Belgium. Eur J Cancer Prev 2015; 24: 340-2.
  • Moss EL, Redman CWE, Arbyn M, Dollery E, Petry KU, Nieminen P, Myerson N, Leeson S. Colposcopy training and assessment across the member countries of the European federation for colposcopy. Eur J Obstet Gynecol Reprod Biol 2015; 188: 124-8.
  • Nowakowski A, Cybulski M, Sliwczynski A, Chil A, Teter Z, Seroczynski P, Arbyn M, Anttila A. Thimplementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines. BMC Cancer 2015; 15: 279.
  • Ostensson E, Alder S, Elfstrom KM, Sundstrom K, Zethraeus N, Arbyn M, Andersson S. Barriers to and facilitators of compliance with clinic-based cervical cancer screening: population-based cohort study of women aged 23-60 years. PLoS ONE 2015; 10: e0128270.
  • Verdoodt F, Jiang X, Williams M, Schnatz PF, Arbyn M. High-risk HPV testing in the management of atypical glandular cells: a systematic review and meta-analysis. Int J Cancer 2015; in-press.
  • Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJF, Arbyn M. Reaching women who do not participate in the regular cervical cancer screening program by offering self-sampling kits: A systematic review and meta-analysis of randomised trials. Eur J Cancer 2015; in-press.
  • von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavir Res 2015.
  • Arbyn M, Annemans L, Vandenbroecke A. Screening for cervical cancer in Belgium. In: Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009; 45: 2686-7.
  • Arbyn M, Raifu AO, Antoine J. Trends of cervical cancer mortality in Europe. IPH/EPI-REPORTS 2009; D/2009/2505/41: 1-54.
  • Arbyn M, Rebolj M, de Kok IM, Becker N, O'Reilly M, Andrae B. Thchallenges for organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer 2009; 45: 2671-8.
  • Arbyn M, Martin-Hirsch P, Wentzensen N. Human papillomavirus-based triage of women showing a cervical cytology result of borderline or mild dyskaryosis. BJOG 2010; 117: 641-4.
  • Arbyn M, Antoine J, Valerianova Z, Mägi M, Stengrevics A, Smailyte G, Suteu O, Anttila A, Micheli A. Trends in cervical cancer incidence and mortality in Bulgaria, Estonia, Latvia, Lithuania and Romania. Tumori 2010; 96: 517-23.
  • Arbyn M, Simoens C, Van Damme P, Scharpantgen A, Meijer CJLM, Beutels P. Introduction of HPV vaccination in Belgium, Luxembourg and the Netherlands. Gynecol Obstet Invest 2010; 70: 152-60.
  • Arbyn, M., Van Casteren, V., and Van Hoof, E. Prevention of Cervical Cancer in Belgium: Anno 2011. PHS Report 2010/010, 1-118. 2011. Brussels, Scientific Institute of Public Health (WIV-ISP).
  • Arbyn, M., Simoens, C., Fabri, V., and Swennen, B. Prophylactic vaccination of girls and female adolescents against human papilomavirus infection (Belgium, 2007-2009). IPH/EPI-REPORTS , 1-50. 2011. Brussels, Scientific Institute Public Health (WIV-ISP); Agence Intermutualiste/Intermutualistisch Agentschap (AIM/IMA).
  • Arbyn M, Van Nieuwenhuyse A, Bogers J, de Jonge E, Op De Beeck L, Mathei C, Buntinx F. Cytological screening for cervical cancer in the province of Limburg, Belgium. Eur J Cancer Prev 2011; 20: 18-24.
  • Arbyn M, Antoine J, Mägi M, Smailyte G, Stengrevics A, Suteu O, Valerianova Z, Bray F, Weiderpass E. Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. Int J Cancer 2011; 128: 1899-907.
  • Arbyn M, Tommasino M, Depuydt C, Dillner J. Artwenty human papillomavirus types causing cervical cancer? J Pathol 2014; 234: 431-5.
  • Arbyn M, Fabri V, Temmerman M, Simoens C. Attendance at cervical cancer screening and use of diagnostic and therapeutic procedures on the uterine cervix assessed from individual health insurance data (Belgium, 2002-2006). PLoS ONE 2014; 9: e92615.
  • Geraets D, Cuschieri K, Koning M, van Doorn L, Snijders P, Meijer CJLM, Quint W, Arbyn M. Clinical evaluation of a GP5+/6+-based Luminex assay having full high-risk HPV genotyping capability and an internal control. J Clin Microbiol 2014; 52: 3996-4002.
  • Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsague X, Laporte L, Bosch FX, de SS, Trottier H. HPDNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 2014; 15: 1319-31.
  • Raifu AO, Arbyn M. Description of cervical cancer mortality in Belgium using Bayesian age-period-cohort models. Arch Public Health 2009; 67: 100-15.
  • Simoens C, Sabbe M, Van Damme P, Beutels P, Arbyn M. Introduction of human papillomavirus (HPV) vaccination in Belgium, 2007-2008. Eurosurveillance 2009; 14: pii=19407- .​